Versatile strategy for controlling the specificity and activity of engineered T cells. - Wikidata - awgldk - TriplyDB

Versatile strategy for controlling the specificity and activity of engineered T cells.

Versatile strategy for controlling the specificity and activity of engineered T cells.

http://www.wikidata.org/entity/Q34045831

about

CAR T Cell Therapy: A Game Changer in Cancer Treatment At the Interface of Chemical and Biological Synthesis: An Expanded Genetic Code.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells An oxygen sensitive self-decision making engineered CAR T-cell.Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer.A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.New development in CAR-T cell therapy.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.Tumor-targeting domains for chimeric antigen receptor T cells.The Principles of Engineering Immune Cells to Treat Cancer.Engineering Chimeric Antigen Receptors.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Driving better and safer HER2-specific CARs for cancer therapy.A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members.Regulation of T cell proliferation with drug-responsive microRNA switches.T cells expressing chimeric antigen receptor promote immune tolerance.Human antibody-based chemically induced dimerizers for cell therapeutic applications.mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting.Expanding and reprogramming the genetic code.Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.Engineering chimeric antigen receptor-T cells for cancer treatment.Playing with the molecules of life.Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells.Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.The development of CAR design for tumor CAR-T cell therapy.Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.Genetically enhanced T lymphocytes and the intensive care unit.The application of CAR-T cell therapy in hematological malignancies: advantages and challenges Therapeutic applications of genetic code expansion Synthetic immunology: T-cell engineering and adoptive immunotherapy

P2860

Q26822769-15B03042-28D9-4D8E-94C8-C1FFA71A9F13 Q30390524-7895BF61-0200-4AFB-AD3A-28FB923060F6 Q33833475-9E76CE45-EB8D-4553-8A96-B371DA0169BA Q34047851-64C98D1E-530A-42F3-BDB8-A5B077F02B87 Q36551673-D0961E6B-651B-4E5C-A7F0-A644725353C3 Q37551219-F4021630-4718-4679-9F62-6F119124C76E Q37555940-2D4DB453-2876-49EC-902A-2F57AB679528 Q37658246-12FC1A9C-97FA-47B7-862C-16780941BC61 Q38830813-B79B316E-F39F-438F-A9E0-2089E18D03E9 Q39037477-1B949A10-41DC-4501-AECB-2071463B5EC5 Q39045535-963120F5-5EE3-4F8A-93AB-C60ECC6F85F2 Q39130457-91B3FD79-81A5-4BF2-A71B-746F7B669033 Q39276909-17EAEC04-2623-4952-B062-9049932D4AD3 Q39280002-C7CB5E04-331D-4BDF-B7C7-A0055738CE75 Q41835996-E5746BD4-2131-4706-9080-3EECC7B32895 Q42378925-FD86ED8A-6915-42C9-8C60-49BD318A5B42 Q45950927-8775A5DE-1816-48DC-A4D7-385E6F5365FD Q46045077-447CCE5E-05DF-4279-AAA1-F7860A887521 Q46341715-8E3E40DF-CA79-41C6-87A7-A56AB6D4789D Q47141728-013D0435-91CA-4676-AAAF-DF861E42D439 Q47599337-D14337D4-6497-40F2-B1DC-A5B4697516F5 Q49210694-9EC37ABE-33A0-4D4D-9142-C3EA5F0A4D7B Q49962991-106A56E2-402E-4F43-ACDB-7AE0273F68DA Q49968034-E4E2AB27-76B4-4FA5-82F6-0A7EF4BBD518 Q50315378-E4723A20-4B51-4DFD-B39C-D09063700CC0 Q50531950-93F00681-ADB2-49F7-9F63-5FB71E0F39EF Q52641562-956119A0-979A-47C9-B477-12EFB247D426 Q52646462-A1EA52DC-6E97-4714-8E30-B314E6359B09 Q55322285-9E24030F-F291-4C1B-A60C-BFC493D918A7 Q55380614-F5E649D9-DF36-43F2-9004-B4CF1FCD9987 Q57177485-5B1B6BBC-039D-4714-8501-BA69119F59DF Q57818219-CB907961-CFCC-4FFB-9A87-7858F6F2355E Q57823195-5BA1DA5A-68C6-4DF3-BC77-DCFD3F29B0E3

P2860

Versatile strategy for controlling the specificity and activity of engineered T cells.

http://www.wikidata.org/entity/Q34045831

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Versatile strategy for controlling the specificity and activity of engineered T cells.

@ast

Versatile strategy for controlling the specificity and activity of engineered T cells.

@en

Versatile strategy for controlling the specificity and activity of engineered T cells.

@nl

type

label

Versatile strategy for controlling the specificity and activity of engineered T cells.

@ast

Versatile strategy for controlling the specificity and activity of engineered T cells.

@en

Versatile strategy for controlling the specificity and activity of engineered T cells.

@nl

prefLabel

Versatile strategy for controlling the specificity and activity of engineered T cells.

@ast

Versatile strategy for controlling the specificity and activity of engineered T cells.

@en

Versatile strategy for controlling the specificity and activity of engineered T cells.

@nl

P1433

Q34045831-ECD30564-12F6-4DB6-9233-9A77285CB1B2

P1476

Q34045831-BBD72F2B-3051-491E-9C7A-927ECB7844DA

P2093

Q34045831-0A7804AB-701D-4F62-9CCC-3629877C6B41

Q34045831-0EA09E97-7F91-4D45-BAEA-99477EB0DBB6

Q34045831-10613BD3-437C-49E6-AED5-FF1951774945

Q34045831-1290F2D1-B234-4CBB-919D-8D07256D56FA

Q34045831-1E45D912-A4EA-495C-9A5C-BAA769AD50FC

Q34045831-24BDD6D3-C540-4C12-9893-700AA46B83C3

Q34045831-2C6FC50C-188C-4A45-94B1-42260429C6E7

Q34045831-4D3A9014-5E4A-4900-8690-7BDB16800391

Q34045831-62577B4C-B723-4284-B49A-82530D9D71A3

Q34045831-66ACDEBF-47EE-43B4-B334-BD0675F484E2

P2860

Q34045831-026F3867-BC90-4736-94FC-08FF3A0A3351

Q34045831-070CE555-F192-451C-B48C-D054E657C95F

Q34045831-08462839-AFC6-4226-B1FA-91DF20C38FA7

Q34045831-088E10D7-42A4-43D6-96C6-849E9D088E8E

Q34045831-08C1883F-26F7-4720-8A2C-6C083F2A0A7B

Q34045831-09E1703F-657A-4701-9E4D-0CB6E7B4D2E6

Q34045831-0C7E4584-0BDB-4BD6-BF6E-A2D37771F41F

Q34045831-0CF635C8-47F1-4417-8785-17A43C39495B

Q34045831-14F500D4-E48E-491F-912E-93D879977141

Q34045831-15523585-3861-4F14-9BFA-52C698BF264E

P304

Q34045831-E9FD5363-5CAE-4D03-83B7-A699F278D65B

P31

Q34045831-87B17D47-BBC1-46B2-8945-FA9F43FFAA5D

P356

Q34045831-E06734C2-C605-414B-A6E9-2561DA9521C4

P407

Q34045831-76A7335F-8A1E-4D84-961C-7F3A17C83DFF

P433

Q34045831-59FBE6AB-94AA-4466-A63A-A16DD3A8A269

P478

Q34045831-BD185C6B-743C-4C6C-80B5-A9A36DC72207

P577

Q34045831-988EC543-C209-4BD9-A6D2-4C452369EB1B

P5875

Q34045831-308CD80B-CA16-4ED5-8067-3CD34F19B17E

P698

Q34045831-6A32106C-B718-4FC6-BDD9-81E7E92C1DE9

P932

Q34045831-19AF4C56-156A-4520-B0C4-F7C72047A643

P356

PNAS.1524193113

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Versatile strategy for controlling the specificity and activity of engineered T cells.

@en

P2093

Bryan R Fonslow

http://www.w3.org/2001/XMLSchema#string

Chan Hyuk Kim

http://www.w3.org/2001/XMLSchema#string

David T Rodgers

http://www.w3.org/2001/XMLSchema#string

Holly M Pugh

http://www.w3.org/2001/XMLSchema#string

Hwa Young Yun

http://www.w3.org/2001/XMLSchema#string

James N Kochenderfer

http://www.w3.org/2001/XMLSchema#string

Jennifer S Y Ma

http://www.w3.org/2001/XMLSchema#string

Ji Young Kim

http://www.w3.org/2001/XMLSchema#string

Min Soo Kim

http://www.w3.org/2001/XMLSchema#string

Oded Singer

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Chimeric antigen receptor therapy for cancer

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.

Structural Basis of the CD8 /MHC Class I Interaction: Focused Recognition Orients CD8 to a T Cell Proximal Position

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Inducible apoptosis as a safety switch for adoptive cell therapy

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

P304

E450-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1524193113

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290432607

http://www.w3.org/2001/XMLSchema#string

P698

26759368

http://www.w3.org/2001/XMLSchema#string

P932

4743826

http://www.w3.org/2001/XMLSchema#string